This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT00148512 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Boehringer Ingelheim |
| Enrollment | 254 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Parkinson Disease |
| Interventions | 1. Tesofensine (NS 2330) |
| Start | Mar 2003 |
| Primary completion | Feb 2005 |
| Study completion | Feb 2005 |
| Results posted | Not yet |
| Registry last updated | Oct 29, 2013 |
Compounds on this site that cite this trial
What the registry says the trial is about
The primary objective of this exploratory study is to investigate the efficacy and safety of tesofensine in daily doses (from 0.125 mg to 1.0 mg) in comparison to placebo, over a 14-week treatment period in levodopa treated Parkinson patients with motor fluctuations.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
